2-phenoxyadamantane

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-phenoxyadamantane
• 英文别名: 2-Phenoxyadamantane
• 化学式: C₁₆H₂₀O
• 分子量: 228.334
• InChiKey: WNGDSWMSZUOWEE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  碘苯 、 2-金刚烷醇 在 copper(l) iodide 、 potassium phosphate tribasic 、 4-吡咯烷基吡啶 作用下， 以 甲苯 为溶剂， 反应 10.0h， 以97%的产率得到2-phenoxyadamantane
  参考文献：
  名称：

  Ullmann CO coupling of sterically hindered secondary alcohols using excess amount of strongly coordinating monodentate ligands

  摘要：

  A new effective copper catalyzed C-O coupling reaction using excess amount of strongly coordinating monodentate ligands was successfully developed. Among the DMAP-type monodentate ligands, 4-pyrrolidinopyridine afforded the best results. The developed reaction is widely applicable for the synthesis of various hindered or acyclic secondary alkyl-aryl ethers. In this study, a novel and remarkable acceleration of the coupling reaction using excess amount of monodentate ligands was discovered. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2017.01.095

文献信息

• [EN] FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF<br/>[FR] COMPOSÉS À CYCLES CONDENSÉS, COMPOSITION PHARMACEUTIQUE ET UTILISATIONS ASSOCIÉES
  申请人：SHANGHAI DE NOVO PHARMATECH CO LTD

  公开号：WO2016131380A1

  公开（公告）日：2016-08-25

  This disclosure is related to a fused-ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the fused ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, preparation methods thereof, and use thereof in modulating activity of indoleamine 2, 3-dioxygenase (IDO) and/or tryptophan 2, 3-dioxygenase (TDO). This disclosure further provides methods of treating IDO and/or TDO-associated diseases, including cancer, viral infection and autoimmune diseases.

  这份披露涉及到式(I)的融合环化合物和/或其药学上可接受的盐，包括式(I)的融合环化合物和/或其药学上可接受的盐的药物组合物，其制备方法，以及在调节吲哚胺2,3-二氧化酶(IDO)和/或色氨酸2,3-二氧化酶(TDO)活性中的应用。这份披露还提供了治疗IDO和/或TDO相关疾病的方法，包括癌症、病毒感染和自身免疫疾病。
• Fused-ring compounds, pharmaceutical composition and uses thereof
  申请人：SHANGHAI DE NOVO PHARMATECH CO., LTD.

  公开号：US10202388B2

  公开（公告）日：2019-02-12

  This disclosure is related to a fused-ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the fused ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, preparation methods thereof, and use thereof in modulating activity of indoleamine 2, 3-dioxygenase (IDO) and/or tryptophan 2, 3-dioxygenase (TDO). This disclosure further provides methods of treating IDO and/or TDO-associated diseases, including cancer, viral infection and autoimmune diseases.

  本公开涉及一种式(I)的熔环化合物和/或其药学上可接受的盐、一种包含式(I)的熔环化合物和/或其药学上可接受的盐的药物组合物、其制备方法以及其在调节吲哚胺2，3-二氧化酶(IDO)和/或色氨酸2，3-二氧化酶(TDO)活性中的用途。本公开进一步提供了治疗IDO和/或TDO相关疾病的方法，包括癌症、病毒感染和自身免疫性疾病。
• FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF
  申请人：SHANGHAI DE NOVO PHARMATECH CO., LTD.

  公开号：US20180022752A1

  公开（公告）日：2018-01-25

  This disclosure is related to a fused-ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the fused ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, preparation methods thereof, and use thereof in modulating activity of indoleamine 2, 3-dioxygenase (IDO) and/or tryptophan 2, 3-dioxygenase (TDO). This disclosure further provides methods of treating IDO and/or TDO-associated diseases, including cancer, viral infection and autoimmune diseases.
• Ullmann CO coupling of sterically hindered secondary alcohols using excess amount of strongly coordinating monodentate ligands
  作者：Hayato Sugata、Tetsu Tsubogo、Yoshitaka Kino、Hiromi Uchiro

  DOI：10.1016/j.tetlet.2017.01.095

  日期：2017.3

  A new effective copper catalyzed C-O coupling reaction using excess amount of strongly coordinating monodentate ligands was successfully developed. Among the DMAP-type monodentate ligands, 4-pyrrolidinopyridine afforded the best results. The developed reaction is widely applicable for the synthesis of various hindered or acyclic secondary alkyl-aryl ethers. In this study, a novel and remarkable acceleration of the coupling reaction using excess amount of monodentate ligands was discovered. (C) 2017 Elsevier Ltd. All rights reserved.